Audentes Therapeutics Inc (NASDAQ:BOLD) VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $36.98, for a total transaction of $369,800.00. Following the sale, the vice president now owns 28,236 shares in the company, valued at approximately $1,044,167.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Suyash Prasad also recently made the following trade(s):

  • On Monday, February 25th, Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $300,600.00.

Shares of BOLD stock traded up $0.02 on Wednesday, hitting $38.23. The stock had a trading volume of 723,716 shares, compared to its average volume of 534,013. The company has a market capitalization of $1.63 billion, a P/E ratio of -11.17 and a beta of 1.85. Audentes Therapeutics Inc has a one year low of $17.95 and a one year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.23). During the same period last year, the company posted ($0.74) EPS. On average, analysts predict that Audentes Therapeutics Inc will post -4.48 EPS for the current year.

A number of research firms recently weighed in on BOLD. William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. Cowen reaffirmed a “buy” rating on shares of Audentes Therapeutics in a research note on Thursday, January 31st. Mizuho reissued a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research note on Friday, February 1st. BidaskClub lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, Chardan Capital raised shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $35.00 to $40.00 in a research note on Monday, February 25th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus price target of $39.92.

Institutional investors have recently made changes to their positions in the business. BB Biotech AG bought a new position in Audentes Therapeutics in the fourth quarter worth about $16,404,000. Dimensional Fund Advisors LP bought a new position in Audentes Therapeutics in the third quarter worth about $6,708,000. Assenagon Asset Management S.A. bought a new position in Audentes Therapeutics in the fourth quarter worth about $1,539,000. Artal Group S.A. raised its holdings in Audentes Therapeutics by 140.0% in the fourth quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $12,792,000 after purchasing an additional 350,000 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. bought a new position in Audentes Therapeutics in the first quarter worth about $264,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 10,000 Shares of Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2019/05/15/insider-selling-audentes-therapeutics-inc-bold-vp-sells-10000-shares-of-stock.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: What Does Beta Mean In Stock Selection

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.